Downtrend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend down since Mar 27 · inside the Ichimoku cloud · RSI 43 · MACD above its signal · at its 52-week low
None of the 29 investors followed here reported a position in BTTX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a BTTX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for BTTX.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 100.0 | 50.0 | -33.3 | -50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2024 | -3.0 | -16.1 | -91.2 | -7.1 | -15.4 | 13.6 | -52.0 | -98.3 | 0.0 | 0.0 | 0.0 | 0.0 | −99.9% |
| 2023 | 24.0 | -12.4 | -41.7 | 66.4 | -39.9 | 54.3 | -30.9 | -16.9 | -41.0 | -61.1 | 37.7 | -0.4 | −82.4% |
| 2022 | -17.0 | -25.9 | -30.8 | -53.9 | 98.5 | -13.8 | 42.3 | -23.0 | 2.9 | -11.9 | -5.8 | -24.3 | −76.2% |
| 2021 | -23.8 | -34.4 | −50.0% |
No analyst coverage for this instrument.
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis ,and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
No recent headlines.